VPS72 Link to Liver Cancer, Lipid Metabolism identified

⁤ Updated June 06, 2025
⁢ ⁢

A⁢ novel regulatory axis⁤ involving VPS72 appears linked to ⁤dysregulated lipid metabolism in hepatocellular carcinoma (HCC), suggesting potential therapeutic targets, according to a study published in Advanced Science. Researchers identified VPS72 as an epigenetic regulator of lipid metabolism within HCC, crucial in the interplay between cancer development and lipid homeostasis.

HCC, the most common primary liver cancer in adults, ranked as the sixth leading cause of cancer-related deaths in the U.S. and the fourth ‍most diagnosed cancer globally in 2022. Dysregulation of lipid metabolism in hepatocytes is central to HCC’s development, leading to abnormal lipid accumulation. Major risk factors include metabolic dysfunction-associated steatohepatitis (MASH) and viral hepatitis.

MASH, previously known as nonalcoholic steatohepatitis, is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), often linked⁢ to obesity and diabetes. It involves liver inflammation due to excess fat, potentially ⁢causing progressive liver damage and is associated with ⁤high blood lipids and blood sugar. The Cleveland Clinic ‍estimates that MASLD affects up to 25%⁢ of U.S. adults, with about 20% of them having MASH. Untreated, it can lead to HCC.

Building on prior evidence linking VPS72 ⁢to HCC progression, investigators analyzed TCGA ‍Liver Hepatocellular Carcinoma (LIHC) patient data. They observed⁤ a ‍significant positive correlation between VPS72 copy number and its expression, suggesting that early oncogenic amplification of VPS72 may drive its overexpression, contributing to HCC development. The⁢ VPS72 gene was found in extra copies in over⁢ half the samples, indicating gains may play a key role in HCC pathogenesis.

The study further revealed that VPS72 ‍expression was noticeably higher in ⁤tumor tissues compared to noncancerous controls. Survival ‍analysis showed a strong association between elevated VPS72 expression and reduced overall survival. Researchers found ⁢that VPS72 overexpression activates mTORC1 signaling,⁢ promoting⁣ lipid synthesis and driving HCC progression. VPS72 modulates the epigenetic landscape by enhancing DNA methylation at the ATF3 promoter,resulting in ATF3 repression and subsequent activation of mTORC1.

The identified VPS72-ATF3-mTORC1-lipogenesis axis highlights the oncogenic potential of VPS72 and establishes a new model for understanding the epigenetic regulation of metabolic reprogramming in HCC.⁣ Because ATF3 regulates diverse metabolic pathways, abnormal VPS72 expression may have broader consequences beyond lipid metabolism, the authors wrote.

The authors emphasized that thier findings ⁤suggest the possibility of therapeutically targeting VPS72 or its interaction‍ with H2A.Z. Disrupting this axis could offer a novel strategy to inhibit lipid biosynthesis and tumor growth. They called for future studies‍ to clarify additional pathways regulated by VPS72 and explore its potential as a therapeutic target across different cancer types.

“Our research shows that the gene VPS72 plays ⁤2 key roles in liver cancer (HCC):‍ it affects both how genes are controlled and how fat metabolism goes wrong. the findings‍ help explain how liver cancer develops and suggest new⁢ ways to treat cancers driven by abnormal fat metabolism,”

What’s next

Future research will focus on ⁤clarifying additional pathways regulated by VPS72‍ and exploring its potential as a therapeutic target across different cancer types, potentially leading to new treatments for liver cancer and other cancers driven by abnormal fatty‍ acid metabolism.